Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

BACKGROUND: In a single-group, phase 1b trial, avelumab plus axitinib resulted in objective responses in patients with advanced renal-cell carcinoma. This phase 3 trial involving previously untreated patients with advanced renal-cell carcinoma compared avelumab plus axitinib with the standard-of-car...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:N Engl J Med
Autori principali: Motzer, Robert J., Penkov, Konstantin, Haanen, John, Rini, Brian, Albiges, Laurence, Campbell, Matthew T., Venugopal, Balaji, Kollmannsberger, Christian, Negrier, Sylvie, Uemura, Motohide, Lee, Jae L., Vasiliev, Aleksandr, Miller, Wilson H., Gurney, Howard, Schmidinger, Manuela, Larkin, James, Atkins, Michael B., Bedke, Jens, Alekseev, Boris, Wang, Jing, Mariani, Mariangela, Robbins, Paul B., Chudnovsky, Aleksander, Fowst, Camilla, Hariharan, Subramanian, Huang, Bo, di Pietro, Alessandra, Choueiri, Toni K.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6716603/
https://ncbi.nlm.nih.gov/pubmed/30779531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1816047
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi